{"schema_version":"secwatch.filing_event.v1","accession":"0001326732-25-000002","form_type":"8-K","ticker":"XNCR","cik":"0001326732","company_name":"Xencor Inc","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.311285+00:00","generated_at":"2026-05-28T02:57:07.132070+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Xencor: $707M cash; XmAb541 selectivity; plamotamab B-cell depletion; XmAb808 dose escalation; vudalimab enrollment done","bullets":["Preliminary cash & marketable securities ~$707M at Dec 31, 2024, up from $697M in 2023; expected to fund ops into 2028.","New preclinical data shows XmAb541 (CLDN6 x CD3) selective binding to CLDN6 over CLDN9.","Plamotamab (CD20 x CD3) Phase 1 data shows deep peripheral B-cell depletion in lymphoma patients.","XmAb808 (B7-H3 x CD28) has resumed dose escalation in clinical study.","Enrollment completed in three ongoing vudalimab (PD-1 x CTLA-4) studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001326732-25-000002","json":"https://secwatch.observer/filing/0001326732-25-000002.json","markdown":"https://secwatch.observer/filing/0001326732-25-000002.md","text":"https://secwatch.observer/filing/0001326732-25-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326732/000132673225000002/0001326732-25-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326732/000132673225000002/xncr-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T02:57:07.132070+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}